Latest Middle East Market News

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.

Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.

X2M Connect reports a 43% revenue decline in FY25 but improves gross margins and expands into the Middle East and renewable energy sectors, setting a positive outlook for FY26.

Breville Group Limited reported robust FY25 results with double-digit revenue and profit growth, successfully navigating US-China tariff challenges through strategic manufacturing diversification and market expansion.

X2M Connect Limited has completed a $309,000 entitlement offer by issuing 23.76 million new shares and options, while a substantial shortfall of nearly 127 million shares remains available for placement.

SRJ Technologies has taken a strategic leap by acquiring a UAE entity registered with a regional National Oil Company, positioning itself for direct contracting in the Middle East energy sector. This move is supported by a recent capital raise and ongoing restructuring to sharpen its regional focus.

Stealth Group Holdings has secured exclusive distribution rights for major global consumer brands in Australia and New Zealand, aiming to accelerate revenue growth and expand its digital footprint.

SunRice reported a slight decline in FY25 revenue to $1.85 billion but achieved improved profitability, driven by strategic acquisitions and operational efficiencies. The company is investing in sustainability and capacity upgrades as it pursues its 2030 Growth Strategy.

SRJ Technologies reported a remarkable 178% increase in Q4 FY24 cash receipts, driven by strong contract activity and strategic partnerships, including a key Middle East market entry. Despite some project delays, the company remains confident in its growth trajectory for FY25.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.